CD274 and colorectal carcinoma: Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis are now widely used, and the composition of the gut microbiota in CRC patients is associated with the therapeutic efficacy of anti-PD-L1 monoclonal antibodies (24).